India bioeconomy roadmap to 2035
Analysis based on 14 articles · First reported Jul 16, 2026 · Last updated Jul 17, 2026
The roadmap signals strong government support for India's biotechnology sector, likely boosting investor confidence and attracting capital to biotech startups and related industries. Long-term projections of significant GDP contribution and job creation may positively impact market sentiment toward Indian biotech firms and the broader economy.
India — NITI Aayog unveiled a roadmap on July 16, 2026, projecting India's bioeconomy to reach USD 691 billion by 2035, creating over 30 million jobs and positioning India among the top three global biotechnology powers. Union Minister Jitendra Singh (politician) launched the plan, emphasizing India's readiness to lead the biotech-driven fourth industrial revolution. The roadmap proposes six National BioMissions covering gene and cell therapies, climate-resilient agriculture, synthetic biology, disease surveillance, marine biotechnology, and next-generation biopharmaceuticals. It also recommends a Rs 50,000-crore BioEconomy Growth Fund for 2026-2035, along with PLI-style incentives, faster regulatory approvals, and stronger intellectual property protection. Singh announced the introduction of an engineering biology course, the first of its kind in India. The roadmap notes India's bioeconomy has grown 16-fold from USD 10 billion in 2014 to USD 195.3 billion in 2025, contributing 4.8% to GDP. The long-term vision targets USD 2.6 trillion by 2047, contributing 8-10% of GDP.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard